Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer.

Ashley M HopkinsMichael J SorichAndrew J McLachlanChristos S KarapetisJohn O MinersMadelé van DykAndrew Rowland

Published in: JCO precision oncology (2023)

To our knowledge, this study provides the first data to assist clinicians' understanding of the drug interaction risk associated with administering ritonavir-containing COVID-19 therapies to patients with cancer who are currently being treated with KIs. These data may support clinicians to make more informed dosing decisions for patients with cancer undergoing treatment with KIs who require treatment with ritonavir-containing COVID-19 antiviral therapies.

Keyphrases

coronavirus disease
sars cov
small molecule
healthcare
electronic health record
antiretroviral therapy
big data
emergency department
smoking cessation
newly diagnosed